BiotechTube
ExcepGen

ExcepGen

Boston, United States· Est.
excepgen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ExcepGen is a private, pre-clinical stage biotech developing a novel platform, RNAx, to create more tolerable RNA vaccines and therapeutics. The platform addresses a key limitation of current nucleic acid medicines—excessive innate immune activation—by encoding a regulatory protein within the mRNA itself. Led by a team with expertise in biochemistry and synthetic biology, the company is advancing initiatives in self-amplifying, trans-amplifying, and conventional mRNA vaccines, aiming to unlock the full potential of RNA-based medicine with a safety profile closer to the standard of care.

Infectious Diseases

Technology Platform

RNAx platform: an mRNA-encoded protein designed to dampen the innate immune response to RNA and lipid nanoparticles (LNPs), aiming to improve the tolerability of RNA vaccines and therapeutics.

Opportunities

The successful demonstration of improved tolerability could position ExcepGen's platform as a critical enabling technology for the broader RNA field, particularly for dose-sparing self-amplifying mRNA vaccines.
This creates significant partnership and licensing potential with large pharma companies seeking to differentiate their mRNA pipelines.

Risk Factors

The core scientific risk is that modulating the innate immune response may negatively impact vaccine efficacy.
The company also faces intense competition from well-capitalized players and the general risk of platform failure inherent in novel biological approaches.

Competitive Landscape

ExcepGen competes with large mRNA leaders (Moderna, BioNTech, CureVac) and numerous startups all working on next-generation RNA technologies, including improved LNPs, nucleoside chemistry, and circular RNA. Its differentiation lies in its biological, rather than chemical, approach to solving reactogenicity.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →